BioNTech says CTLA-4 drug nearly doubled survival times for lung cancer

Data ReadoutpositivegotistobartPositive

AI Analysis

Summary

BioNTech announced positive clinical data for gotistobart, its CTLA-4 antibody, showing the drug nearly doubled survival times in previously treated lung cancer patients with an 8.5-month survival extension.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

CTLA-4 antibody gotistobart nearly doubled survival times in previously treated lung cancer patients, extending survival by 8.5 months

Importance:7/10

Sentiment:

0.75

CTLA-4immunotherapylung cancersurvival benefitclinical data

Related Companies

$BNTX

Read the original article

Published by Endpoints News on September 14, 2026 6:27 PM

Read Original